Pharsight

Neuraceq patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7807135 LIFE MOLECULAR Stilbene derivatives and their use for binding and imaging amyloid plaques
Mar, 2029

(4 years from now)

Neuraceq is owned by Life Molecular.

Neuraceq contains Florbetaben F-18.

Neuraceq has a total of 1 drug patent out of which 0 drug patents have expired.

Neuraceq was authorised for market use on 19 March, 2014.

Neuraceq is available in solution;intravenous dosage forms.

Neuraceq can be used as neuraceq is a radioactive diagnostic agent for positron emission tomography (pet) imaging of the brain to estimate p-amyloid neuritic plaque density in adult patients with cognitive impairment.

The generics of Neuraceq are possible to be released after 18 March, 2029.

Drugs and Companies using FLORBETABEN F-18 ingredient

Market Authorisation Date: 19 March, 2014

Treatment: Neuraceq is a radioactive diagnostic agent for positron emission tomography (pet) imaging of the brain to estimate p-amyloid neuritic plaque density in adult patients with cognitive impairment

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

NEURACEQ family patents

Family Patents